Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

DDX3X Mutation Endow R-Loop-Dependent Lymphomagenesis

Jie Xiong, Shu Cheng, Hua-man Cai, Yu-Ran Qiu, Wei Li Zhao

Blood (2024) 144 (Supplement 1): 5756.

https://doi.org/10.1182/blood-2024-206718

Published: 2024

Journal Articles

Integration of Deep Learning in Baseline PET/CT and Multi-Omics Data for Prognostic Modeling in Diffuse Large B-Cell Lymphoma: The Clinicalpet Lymphplex Model

Yue Wang, Xue Wang, Xinyun Huang, Ying Qian, Rongji Mu, Qing Shi, Di Fu, Hongmei Yi, Bin-Shen Ou-Yang, Zhuo Han Li, Shu Cheng, Wang Li, Ning Wen, Pengpeng Xu, Wei Li Zhao

Blood (2024) 144 (Supplement 1): 6224.

https://doi.org/10.1182/blood-2024-206537

Published: 2024

Journal Articles

Investigating Prognostic Value of Immunoglobulin Next-Generation Sequencing in B Cell Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy

Yi-Lun Zhang, Lingshuang Sheng, Rong Shen, Wen Wu, Xin Zheng, Li Wang, Shu Cheng, Peng-Peng Xu, Qi-Jie Jian, Bo Peng, Ke Zhang, Fei Pang, Kai Wang, Zi-Xun Yan, Wei-Li Zhao

Blood (2024) 144 (Supplement 1): 6208.

https://doi.org/10.1182/blood-2024-209889

Published: 2024

Journal Articles

Practical Microenvironment Classification in Diffuse Large B-Cell Lymphoma Using Digital Pathology

Yuqing Wang, Shuo Wang, Hongmei Yi, Yue Wang, Haimin Xu, Shuang Tian, Yan Dong, Jing Zhao, Di Fu, Rongji Mu, Shuye Wang, Li Wang, Pengpeng Xu, Wei Li Zhao

Blood (2024) 144 (Supplement 1): 4974.

https://doi.org/10.1182/blood-2024-202864

Published: 2024

Journal Articles

LY007, a Novel Anti-CD20 CAR-T Cell Therapy for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (R/R B-NHL): Results from a Phase 1 Study

Blood (2024) 144 (Supplement 1): 4822.

https://doi.org/10.1182/blood-2024-198296

Published: 2024

Journal Articles

Efficacy and Safety of Chidamide Combined with BEAM Conditioning Regimen in Autologous Transplantation for T-Cell Lymphoma

Yige Shen, Zhong Zheng, Mengmeng Ji, Wei Tang, Wei Li Zhao

Blood (2023) 142 (Supplement 1): 3602.

https://doi.org/10.1182/blood-2023-177562

Published: 2023

Journal Articles

Preliminary Results from a Phase I/II Study of Pomalidomide Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (PRIDE)

Pengpeng Xu, Wang Li, Shu Cheng, Wei Li Zhao

Blood (2023) 142 (Supplement 1): 6229.

https://doi.org/10.1182/blood-2023-186087

Published: 2023

Journal Articles

Survival Patterns of Non-Randomized Patients in the IELSG37 Study: Deauville Score 4 Is Not Necessarily Associated with Poor Outcome in Primary Mediastinal Lymphoma

Emanuele Zucca, Luca Ceriani, Andrew S. Davies, Giovannino Ciccone, Umberto Ricardi, Alice Di Rocco, Iryna Kryachok, Barbara Botto, Monica Balzarotti, Alessandra Tucci, Vittorio Ruggero Zilioli, Sara Usai, Luca Arcaini, Elsa Pennese, Anna Dabrowska-Iwanicka, Andrés José María Ferreri, Franceso Merli, Wei Li Zhao, David Hodgson, Codruta Ionescu, Luigi Rigacci, Claudia Cellini, Caterina Stelitano, Stefano Volpetti, Carla Minoia, Michele Spina, Alexander Fossa, George Mikhaeel, Kate Cwynarski, Andrea Janikova, Yana Stepanishyna, Mats Jerkeman, Andreas Huettmann, Maria Gomes da Silva, Don A. Stevens, Sally F Barrington, Bogdan Małkowski, Ur Metser, Annibale Versari, Stephane Chauvie, Oreste Bagni, Kelly Cozens, Sonia Perticone, Nicoletta Ielmini, Letizia Deantonio, Jan Walewski, Marek Trneny, Mary Gospodarowicz, Franco Cavalli, Peter Johnson, Maurizio Martelli

Blood (2023) 142 (Supplement 1): 1718.

https://doi.org/10.1182/blood-2023-174093

Published: 2023

Journal Articles

Update of Swatch Study: Selinxor Combined with Lenalidomide and Rituximab (R2) in Adults with Diffuse Large B Cell Lymphoma (DLBCL) and Indolent Non-Hodgkin's Lymphoma (iNHL)

Li Wang, Zhiming Li, Lina Zhang, Liling Zhang, Jay Mei, Wei Li Zhao

Blood (2023) 142 (Supplement 1): 6235.

https://doi.org/10.1182/blood-2023-180535

Published: 2023

Journal Articles

Efficacy and Safety of Orelabrutinib in Relapsed/Refractory Waldenstrom's Macroglobulinemia Patients

Blood (2021) 138 (Supplement 1): 46.

https://doi.org/10.1182/blood-2021-149350

Published: 2021

Journal Articles

Trial in Progress: Pomalidomide Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (PRIDE)

Pengpeng Xu, Li Wang, Shu Cheng, Wei Li Zhao

Blood (2021) 138 (Supplement 1): 4562.

https://doi.org/10.1182/blood-2021-146851

Published: 2021

Journal Articles

Trial in Progress: Real-World Safety and Effectiveness of Brentuximab Vedotin in Adults with CD30+ Lymphoma in China

Pengpeng Xu, Mingci Cai, Wendy Zhang, Wei Li Zhao

Blood (2021) 138 (Supplement 1): 4552.

https://doi.org/10.1182/blood-2021-149031

Published: 2021

Journal Articles

Chidamide Plus R-CHOP21 in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Results of a Phase II Study

Muchen Zhang, Ying Fang, Pengpeng Xu, Shu Cheng, Li Wang, Wei-li Zhao

Blood (2018) 132 (Supplement 1): 2968.

https://doi.org/10.1182/blood-2018-99-113942

Published: 2018

Journal Articles

Synergic Effect of Histone Deacetylase Inhibitor Chidamide with Doxorubicin on Diffuse Large B-Cell Lymphoma with Double BCL2/MYC Expression

Ying Fang, Feng Liu, Wei-li Zhao

Blood (2018) 132 (Supplement 1): 4104.

https://doi.org/10.1182/blood-2018-99-114079

Published: 2018

Journal Articles

Efficacy and Safety of JWCAR029 in Adult Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Zixun Yan, Wen Wang, MD, Zhong Zheng, Ming Hao, Su Yang, James Li, Shu Cheng, Li Wang, Wei-li Zhao

Blood (2018) 132 (Supplement 1): 4187.

https://doi.org/10.1182/blood-2018-99-115769

Published: 2018

Journal Articles

A Phase II Study of Chidamide Plus R-CHOP in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: An Interim Analysis

Pengpeng Xu, Muchen Zhang, Ying Fang, Li Wang, Shu Cheng, Wei-li Zhao

Blood (2017) 130 (Supplement 1): 4126.

https://doi.org/10.1182/blood.V130.Suppl_1.4126.4126

Published: 2017

Journal Articles

MicroRNA21 Sensitized B-Lymphoma Cells to ABT-199 through Modulating ICOS/ICOSL-Mediated Interaction of Regulatory T Cells with Endothelial Cells

Zhong Zheng, Peng-Peng Xu, Li Wang, Hui-Jin Zhao, Wei Li Zhao

Blood (2016) 128 (22): 2942.

https://doi.org/10.1182/blood.V128.22.2942.2942

Published: 2016

Journal Articles

Exome Sequencing Identifies Somatic Mutations of DDX3X in Natural Killer/T-Cell Lymphoma

Blood (2014) 124 (21): 1663.

https://doi.org/10.1182/blood.V124.21.1663.1663

Published: 2014

Journal Articles

Cytogenetic and Molecular Features of 1331 Chinese Patients with Primary Acute Lymphoblastic Leukemia (ALL).

Blood (2009) 114 (22): 4718.

https://doi.org/10.1182/blood.V114.22.4718.4718

Published: 2009

Journal Articles

PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor

Wei-Li Zhao, Yan-Yan Liu, Qun-Ling Zhang, Li Wang, Christophe Leboeuf, Yi-Wen Zhang, Jie Ma, José-Francisco Garcia, Yong-Ping Song, Jun-Min Li, Zhi-Xiang Shen, Zhu Chen, Anne Janin, Sai-Juan Chen

Blood (2008) 111 (7): 3867–3871.

https://doi.org/10.1182/blood-2007-08-108654

Published: 2008

NARROW

DDX3X Mutation Endow R-Loop-Dependent Lymphomagenesis

Integration of Deep Learning in Baseline PET/CT and Multi-Omics Data for Prognostic Modeling in Diffuse Large B-Cell Lymphoma: The Clinicalpet Lymphplex Model

Investigating Prognostic Value of Immunoglobulin Next-Generation Sequencing in B Cell Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy

Practical Microenvironment Classification in Diffuse Large B-Cell Lymphoma Using Digital Pathology

LY007, a Novel Anti-CD20 CAR-T Cell Therapy for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (R/R B-NHL): Results from a Phase 1 Study

Efficacy and Safety of Chidamide Combined with BEAM Conditioning Regimen in Autologous Transplantation for T-Cell Lymphoma

Preliminary Results from a Phase I/II Study of Pomalidomide Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (PRIDE)

Survival Patterns of Non-Randomized Patients in the IELSG37 Study: Deauville Score 4 Is Not Necessarily Associated with Poor Outcome in Primary Mediastinal Lymphoma

Update of Swatch Study: Selinxor Combined with Lenalidomide and Rituximab (R2) in Adults with Diffuse Large B Cell Lymphoma (DLBCL) and Indolent Non-Hodgkin's Lymphoma (iNHL)

Efficacy and Safety of Orelabrutinib in Relapsed/Refractory Waldenstrom's Macroglobulinemia Patients

Trial in Progress: Pomalidomide Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (PRIDE)

Trial in Progress: Real-World Safety and Effectiveness of Brentuximab Vedotin in Adults with CD30+ Lymphoma in China

Chidamide Plus R-CHOP21 in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Results of a Phase II Study

Synergic Effect of Histone Deacetylase Inhibitor Chidamide with Doxorubicin on Diffuse Large B-Cell Lymphoma with Double BCL2/MYC Expression

Efficacy and Safety of JWCAR029 in Adult Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

A Phase II Study of Chidamide Plus R-CHOP in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: An Interim Analysis

MicroRNA21 Sensitized B-Lymphoma Cells to ABT-199 through Modulating ICOS/ICOSL-Mediated Interaction of Regulatory T Cells with Endothelial Cells

Exome Sequencing Identifies Somatic Mutations of DDX3X in Natural Killer/T-Cell Lymphoma

Cytogenetic and Molecular Features of 1331 Chinese Patients with Primary Acute Lymphoblastic Leukemia (ALL).

PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only